Paclitaxel injection: Clinical Trials

44 trials of Paclitaxel injection, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

15 unknown, 14 recruiting, 5 active not recruiting, 3 completed. 23 Phase 3, 21 Phase 2, 6 Phase 1, 2 Phase 4, 1 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 323Recruiting 8, Unknown 8, Active not recruiting 3, Completed 2, Not yet recruiting 1, Terminated 1
Phase 221Recruiting 8, Unknown 4, Active not recruiting 3, Terminated 3, Completed 1, Not yet recruiting 1, Withdrawn 1
Phase 16Recruiting 3, Active not recruiting 1, Terminated 1, Unknown 1
Phase 42Unknown 2
Not applicable1Enrolling by invitation 1

Follow Paclitaxel injection: new trials by email Literature Review of Paclitaxel injection trials Research Report on Paclitaxel injection

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
HB0025-C-0301: A Study to Investigate HB0025 Combined With Chemotherapy as First-Line Treatment for Advanced or Recurrent MMR-proficient Endometrial Cancer
HB0025 Injection, Paclitaxel injection, Carboplatin injection - First-line pMMR Endometrial Cancer
Phase 3RecruitingShanghai Huaota Biopharmaceutical Co., Ltd.3332026-10-202026-10-29
A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
LBL-024 for Injection, Cisplatin Injection, Paclitaxel Injection - Advanced Solid Tumour
Phase 2RecruitingNanjing Leads Biolabs Co.,Ltd1102026-02-262026-05-18
Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer
Carboplatin Injection, Paclitaxel Injection - Squamous Non-small Cell Lung Cancer
Phase 3Not yet recruitingShanghai Huaota Biopharmaceutical Co., Ltd.4802026-01-152026-01-22
A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer
LBL-024 for Injection, Paclitaxel injection, Bevacizumab injection - Ovarian Cancer
Phase 1 / Phase 2RecruitingNanjing Leads Biolabs Co.,Ltd1802025-12-022026-08-13
A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer
SHR-1316 Injection, Cisplatin Injection, Carboplatin Injection - Advanced Cervical Cancer
Phase 3RecruitingShanghai Shengdi Pharmaceutical Co., Ltd7202025-10-172026-04-15
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
LBL-024 for Injection, Docetaxel Injection, Bevacizumab Injection - Advanced Solid Tumour
Phase 2RecruitingNanjing Leads Biolabs Co.,Ltd2502025-06-112026-08-27
A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer
SHR-A1811, Carboplatin, Bevacizumab - Ovarian Cancer
Phase 1 / Phase 2RecruitingSuzhou Suncadia Biopharmaceuticals Co., Ltd.1502025-03-182026-09-11
A Study of SHR-A1811 in Subjects With Ovarian Cancer
SHR-A1811, Paclitaxel Injection, Doxorubicin Hydrochloride Liposome Injection - Ovarian Cancer
Phase 3RecruitingJiangsu HengRui Medicine Co., Ltd.3002025-03-132026-04-20
A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma
SHR-A2102 for Injection, Docetaxel Injection, Paclitaxel Injection - Advanced Urothelial Carcinoma
Phase 3RecruitingShanghai Hengrui Pharmaceutical Co., Ltd.4022025-02-122025-07-17
Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC
Pembrolizumab 25 mg/ml, Paclitaxel injection - Triple-negative Breast Cancer
Phase 2RecruitingUNICANCER3542024-12-272026-07-24
Neoadjuvant Chemotherapy With WH002 in Women With HER2-negative Breast Cancer
WH002, paclitaxel injection - Breast Cancer
Phase 2CompletedBeijing Wehand-Bio Pharmaceutical Co., Ltd402024-09-102026-06-09
A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
SHR-9839 for Injection, SHR-A1921 for Injection, SHR-A2009 for Injection - Advanced Solid Tumors
Phase 1 / Phase 2RecruitingShanghai Hengrui Pharmaceutical Co., Ltd.1562024-07-022026-05-11
A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)
LVGN6051 Monoclonal Antibody Injection, toripalimab Injection, Paclitaxel injection - Head and Neck Squamous Cell Carcinoma
Phase 2Active not recruitingLyvgen Biopharma Holdings Limited642024-06-212026-05-19
A Study of Chemoradiotherapy With SHR-1316 For Treatment of Locally Advanced Cervical Cancer
SHR-1316, Cisplatin Injection/Carboplatin Injection, External Beam Radiotherapy (EBRT)/Brachytherapy - Locally Advanced Cervical Cancer
Phase 2UnknownShanghai Shengdi Pharmaceutical Co., Ltd562024-03-202024-12-24
DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
Disitamab Vedotin Injection, Cadonilimab Injection, Paclitaxel Injection - Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Phase 2 / Phase 3RecruitingRemeGen Co., Ltd.902024-02-222024-04-03
A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer
TQB2868 injection, Paclitaxel injection, Cisplatin injection - Cervical Cancer
Phase 2WithdrawnChia Tai Tianqing Pharmaceutical Group Co., Ltd.2023-08-012023-11-22
Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric Cancer
Tislelizumab, 5Fu, Paclitaxel injection - Gastric Cancer
Phase 2UnknownFujian Cancer Hospital392023-07-012023-06-22
A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer
MRG002, Docetaxel Injection, Paclitaxel Injection - Advanced or Metastatic Urothelium Cancer
Phase 3RecruitingShanghai Miracogen Inc.2902023-04-062023-04-13
Onvansertib + Paclitaxel In TNBC
Onvansertib, Paclitaxel - Breast Cancer, Invasive Breast Cancer
Phase 1 / Phase 2Active not recruitingAntonio Giordano, MD502022-09-302026-11-12
QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer
QL1706, Placebo, Paclitaxel injection - METASTATIC CERVICAL CANCER
Phase 3UnknownQilu Pharmaceutical Co., Ltd.4982022-09-232022-11-30

Showing 20 of 44. Sign in to see all of them.

Conditions studied

Breast Neoplasms (8)  ·  Stomach Neoplasms (7)  ·  Carcinoma, Non-Small-Cell Lung (4)  ·  Ovarian Neoplasms (4)  ·  Uterine Cervical Neoplasms (3)  ·  Head and Neck Neoplasms (2)  ·  Triple Negative Breast Neoplasms (2)  ·  Esophageal Squamous Cell Carcinoma (1)  ·  Inflammatory Breast Neoplasms (1)  ·  Neoplasm Metastasis (1)  ·  Recurrence (1)  ·  Squamous Cell Carcinoma of Head and Neck (1)

Sponsors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (4)  ·  Nanjing Leads Biolabs Co.,Ltd (3)  ·  RemeGen Co., Ltd. (3)  ·  Biotech Pharmaceutical Co., Ltd. (2)  ·  Jiangsu HengRui Medicine Co., Ltd. (2)  ·  Qilu Pharmaceutical Co., Ltd. (2)  ·  Shanghai Hengrui Pharmaceutical Co., Ltd. (2)  ·  Shanghai Huaota Biopharmaceutical Co., Ltd. (2)  ·  Shanghai Shengdi Pharmaceutical Co., Ltd (2)  ·  UNICANCER (2)  ·  Antonio Giordano, MD (1)  ·  BeiGene (1)  ·  Beijing Wehand-Bio Pharmaceutical Co., Ltd (1)  ·  China Medical University, China (1)  ·  Daehwa Pharmaceutical Co., Ltd. (1)

Countries

China (37)  ·  France (2)  ·  Bulgaria (1)  ·  Germany (1)  ·  Hungary (1)  ·  Serbia (1)  ·  South Korea (1)  ·  Spain (1)  ·  United States (1)

Top investigators

Aimin Zang (1)  ·  Aiping Zhou, MD (1)  ·  Airong Wang (1)  ·  Antonio C Giordano, MD, PhD (1)  ·  Baohui Han (1)  ·  Barbara Pistilli, MD (1)  ·  Binghe Xu (1)  ·  Changlu Hu (1)  ·  Elie Rassy, MD (1)  ·  Fangjian Zhou, MD (1)  ·  Fei Ma, MD (1)  ·  Guohua Yu (1)  ·  Haibo Wang (1)

Results publications

PMID 17426445, PMID 24662947, PMID 33130217, PMID 33323401, PMID 34925553, PMID 37158938, PMID 39581197, PMID 39929333, PMID 41344593

NIH funding

2019 (1), 2023 (1)